Pharmaceutical Chemical Rivaroxaban Intermediate CAS 366789-02-8

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Rivaroxaban
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Appearance: White Powder
• CAS No: 366789-02-8
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1kg
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Grade: Phamaceutical Grade
• Molecular Formula: C38h72n2o12
• Active Ingredient: 2-Thiophenecarboxamide
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

Pharmaceutical Chemical Rivaroxaban Intermediate CAS 366789-02-8

Specification of Analysis

Appearance	Powder		Complies
Color	White fine Powder		Complies
Particle Size	100% pass 80 mesh		Complies
Oder	Characteristic		Complies
Taste	Characteristic		Complies
Loss on Drying	≤5.0%		2.20%
Residue on Ignition	≤0.1%		0.05%
Residual acetonemia	≤0.1%		Complies
Residual Ethanol	≤0.5%		Complies
Heave Mentals	≤10ppm		Complies
Na	≤0.1%		<0.1%
Pb	≤3 ppm		Complies
Total Plate	<1000CFU/g		Complies
Yeast & Mold	<100 CFU /g		Complies
E. Coli	Negative		Complies
Salmonella	Negative		Complies

Rivaroxaban is an oral anticoagulant. It is an orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
There is currently no specific way to reverse the anticoagulant effect of rivaroxaban in the event of a major bleeding event, unlike w-arfarin.

Application:

Rivaroxaban can be used to prevent strokes in those with atrial fibrillation due to causes other than heart valvedisease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke)

Rivaroxaban can also be used to prevent the formation of blood clots in the veins (deep venous thrombosis) in adults who have had an operation to replace a hip or knee and for treatment and prevention of acute deep venous thrombosis in adults. It can not be used for prevention of venous thrombosis in hospitalized medically ill patients.